Consistent with these findings, using publicly available patient survival data we indeed identified that USP22high-expressing BLBC and HER2+-BC patients show a poor response to chemotherapeutics and anti-HER2 agents, respectively (Fig. 6B). Here, ERBB2 is linked to breast cancer.